Market By Type, Technology, Age Group, Delivery Mode And Geography | Forecast 2019-2028
A Triton Market Research report on the influenza vaccines market in the Asia-Pacific region determines that it is set to expand at a CAGR of 6.63% in the forecasted period 2019-2028.
Report scope can be customized per your requirements. Request For Customization
The countries studied in the Asia-Pacific influenza vaccines market are:
• South Korea
• China
• ASEAN countries
• Japan
• India
• Australia & New Zealand
• Rest of APAC countries
The rising government initiatives and their continuous funding toward the development of vaccines are the primary factors driving the growth of the influenza vaccines market in the Asia-Pacific region. According to UNICEF (United Nations Children’s Fund), in 2018, the crude birth rate in China and India was 13.4 and 20.7, respectively. The high birth rate in these emerging countries in the region would instigate the demand for influenza vaccines in infants.
Besides, leading players in the market are increasingly adopting strategies such as joint ventures, collaborations and agreements, which is likely to boost the regional market growth. Also, these companies are undertaking rigorous research & development activities to reduce the burden of seasonal influenza through the use of vaccines. All these factors are expected to proliferate the influenza vaccines market in the Asia-Pacific.
In January 2019, over 608,000 flu cases were reported in mainland China, including 143 deaths, which was more than the total number of deaths in the whole of 2017. It is reported that winter is the peak season for outbreaks of influenza in the majority of China, especially the month of January recording the highest cases. All these factors are collectively helping the growth of the influenza vaccines market in the country over the forecasted period.
CSL Limited is a biotherapeutics company, which is engaged in manufacturing and distributing biotherapies. The company provides products for different product categories, including hemophilia, immunoglobulins, albumin and Seqirus. It has two major business operation segments, CSL Behring and Seqirus. Fluad and Flucelvax are the influenza vaccines provided by the company. It is headquartered in Melbourne, Australia.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. ASIA-PACIFIC INFLUENZA VACCINES MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1. QUADRIVALENT IS THE DOMINANT TYPE OF INFLUENZA VACCINE
2.2.2. INJECTION IS FASTEST-GROWING DELIVERY MODE
2.2.3. CELL-BASED TECHNOLOGY IS RAPIDLY GROWING TECHNOLOGY IN THE MARKET
2.2.4. ADULT AGE GROUP IS MAJORLY CONTRIBUTING IN THE MARKET
2.3. PORTER’S FIVE FORCE ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTE
2.3.3. BARGAINING POWER OF SUPPLIERS
2.3.4. BARGAINING POWER OF BUYERS
2.3.5. INTENSITY OF COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR SCORECARD
2.6. MARKET DRIVERS
2.6.1. ADVANCEMENT IN TECHNOLOGY
2.6.2. INITIATIVES TAKEN UP BY THE GOVERNMENT
2.7. MARKET RESTRAINTS
2.7.1. HIGH COST OF DEVELOPMENT
2.8. MARKET OPPORTUNITIES
2.8.1. GROWTH IN THE CASES OF INFLUENZA
2.9. MARKET CHALLENGES
2.9.1. COMPLEX DEVELOPMENT PROCESS
3. INFLUENZA VACCINES MARKET OUTLOOK - BY TYPE
3.1. QUADRIVALENT VACCINE
3.2. TRIVALENT VACCINE
4. INFLUENZA VACCINES MARKET OUTLOOK - BY TECHNOLOGY
4.1. EGG-BASED TECHNOLOGY
4.2. CELL-BASED TECHNOLOGY
5. INFLUENZA VACCINES MARKET OUTLOOK - BY AGE GROUP
5.1. PEDIATRIC AGE GROUP
5.2. ADULT AGE GROUP
6. INFLUENZA VACCINES MARKET OUTLOOK - BY DELIVERY MODE
6.1. INJECTION
6.2. NASAL SPRAY
7. INFLUENZA VACCINES MARKET – ASIA-PACIFIC
7.1. CHINA
7.2. JAPAN
7.3. INDIA
7.4. SOUTH KOREA
7.5. ASEAN COUNTRIES
7.6. AUSTRALIA & NEW ZEALAND
7.7. REST OF ASIA-PACIFIC
8. COMPETITIVE LANDSCAPE
8.1. MERCK SHARP & DOHME CORP
8.2. NOVARTIS AG
8.3. PFIZER INC
8.4. SANOFI
8.5. BIODIEM
8.6. EMERGENT BIOSOLUTIONS INC
8.7. F. HOFFMANN-LA ROCHE LTD
8.8. GLAXOSMITHKLINE PLC
8.9. ABBOTT
8.10. CSL LIMITED
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.1.1. OBJECTIVES OF STUDY
9.1.2. SCOPE OF STUDY
9.2. SOURCES OF DATA
9.2.1. PRIMARY DATA SOURCES
9.2.2. SECONDARY DATA SOURCES
9.3. RESEARCH METHODOLOGY
9.3.1. EVALUATION OF PROPOSED MARKET
9.3.2. IDENTIFICATION OF DATA SOURCES
9.3.3. ASSESSMENT OF MARKET DETERMINANTS
9.3.4. DATA COLLECTION
9.3.5. DATA VALIDATION & ANALYSIS
TABLE 1: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY TYPE, 2019-2028 (IN $ MILLION)
TABLE 4: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 5: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY AGE GROUP, 2019-2028 (IN $ MILLION)
TABLE 6: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY DELIVERY MODE, 2019-2028 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
FIGURE 1: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY SOURCE, 2019 & 2028 (IN %)
FIGURE 2: ASIA-PACIFIC QUADRIVALENT INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 3: ASIA-PACIFIC INJECTION DELIVERY MODEL MARKET, 2019-2028 (IN $ MILLION)
FIGURE 4: ASIA-PACIFIC CELL-BASED TECHNOLOGY MARKET, 2019-2028 (IN $ MILLION)
FIGURE 5: ASIA-PACIFIC ADULT AGE GROUP MARKET, 2019-2028 (IN $ MILLION)
FIGURE 6: PORTER’S FIVE FORCE ANALYSIS
FIGURE 7: MARKET ATTRACTIVENESS INDEX
FIGURE 8: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY QUADRIVALENT VACCINE, 2019-2028 (IN $ MILLION)
FIGURE 9: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY TRIVALENT VACCINES, 2019-2028 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY EGG-BASED TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY CELL-BASED TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY PEDIATRIC AGE GROUP, 2019-2028 (IN $ MILLION)
FIGURE 13: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY ADULT AGE GROUP, 2019-2028 (IN $ MILLION)
FIGURE 14: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY INJECTION, 2019-2028 (IN $ MILLION)
FIGURE 15: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY NASAL SPRAY, 2019-2028 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC INFLUENZA VACCINES MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 17: CHINA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 18: JAPAN INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 19: INDIA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 20: SOUTH KOREA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 21: ASEAN COUNTRIES INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 22: AUSTRALIA & NEW ZEALAND INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 23: REST OF ASIA-PACIFIC INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)